BOSTON, MA—(UPDATED) Patients with severe symptomatic degenerative mitral regurgitation (MR) ineligible for surgery fare just as well when treated with the Pascal device (Edwards Lifesciences) as ...

CHICAGO, IL—In experienced hands, compassionate use of the Pascal transcatheter valve repair system in patients with severe high-risk or inoperable tricuspid regurgitation (TR) can be safe and ...

Tricuspid valve repair with the experimental Pascal device sustained significant early reductions in tricuspid regurgitation and improved quality of life, 1-year results from the CLASP-TR study show. ...

Transcatheter mitral valve repair with the PASCAL device showed high rates of survival and freedom from heart failure rehospitalization at 2 years in the single-arm, safety and efficacy CLASP study.

Please provide your email address to receive an email when new articles are posted on . BOSTON — A novel mitral valve transcatheter edge-to-edge repair system was noninferior to an existing system in ...

Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral regurgitation (DMR) found that the PASCAL ...

SAN FRANCISCO -- The Pascal device remained noninferior to MitraClip for prohibitive surgical risk patients with significant symptomatic degenerative mitral regurgitation (DMR) in full results from ...

BOSTON -- The Pascal device for edge-to-edge mitral valve repair was as safe and effective as the MitraClip device, the pivotal CLASP IID trial showed. In a pre-specified interim analysis of the first ...

Abbott Laboratories (ABT) announced on Monday that it has reached an agreement with Edwards Lifesciences Corp. (EW) to settle all outstanding patent disputes related to heart valve medical devices or ...

BOSTON – September 17, 2022 – Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral ...